Turing Pharmaceuticals, a privately held biopharmaceutical company has announced staff changes and plans for future leadership
Turing
The company has said it recently realigned its business priorities and has taken actions to streamline its operations to focus on its research and development programs and commercial assets.
This follows Turing’s CEO, Martin Shkreli’s arrest having a direct impact on the development of cancer drugs and Ron Tilles, chairman of Turing’s board, being appointed to the position of interim CEO last week.
Tilles said: “Turing was founded to be innovative and entrepreneurial in bringing important new therapies to patient populations that are currently underserved.
“These staff changes put us in the best position to continue executing on our long-term plan.”
In addition, the company announced it has launched the search for a permanent CEO with strong experience in the pharmaceutical sector and plans to expand its board to include new, independent members.
In addition to Tilles, Turing’s leadership team also includes: Eliseo Salinas, president of research and development, chief commercial officer Nancy Retzlaff and Patrick Crutcher, head of business development.
Tilles said: “Though this has been a period of leadership transition for Turing I am confident that the fundamental business model remains strong.”